Gesamtüberlebensdaten der Phase-3-COLUMBUS-Studie: Vergleich von Encorafenib (ENCO) plus Binimetinib (BINI) mit Vemurafenib oder Encorafenib beim BRAF-mutierten Melanom

ASCO Annual Meeting 2018 – Abstract: No. 9504, Dummer R et al.: COLUMBUS-Studie

Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma.

 

Conclusion:

“The best-in-class median PFS of 14.9 and median OS of 33.6 mo suggest that COMBO450 is a promising new regimen for treatment of BRAF-mutant melanoma. SPONSOR: Array BioPharma Inc.”

 

Clinical trial information: NCT01909453

 

Quelle:
Dummer R et al. ASCO 2018. Oral Abstract Session. Melanoma/Skin Cancer. Abstract 9504.

J Clin Oncol 36, 2018 (suppl; abstr 9504)

https://meetinglibrary.asco.org/record/159079/abstract